

FIG. 1 Effect of Taxol and Ceramide on Jurkat Cell Growth Inhibition




FIG. 2
Effect of Serum on Taxol and Ceramide
Induced Jurkat Cell Growth Inhibition





FIG. 3A



A





FIG. 3B



B





FIG. 3C



C






FIG. 3D





D





4/17

FIG. 3F



F

FIG. 3E



E

FIG. 4A

Untreated




FIG. 4B

+25 μ g/ml Ceramide



FIG. 4C

+0.6 ng/ml Paclitaxel




FIG. 4D

+6.0 ng/ml Paclitaxel




FIG. 4E

0.6 ng/ml Paclitaxel
+
25 μ g/ml Ceramide



FIG. 4F


6.0 ng/ml Paclitaxel
+
25 μ g/ml Ceramide



664040-48828260


Taxol and Ceramide Induction of Apoptosis in Jurkat Cells

FIG. 5A (24 Hours)




0.93%

FIG. 5B




0.64%

FIG. 5C




1.16%

FIG. 5D




25.49%

FIG. 5E (48 Hours)




0.77%

FIG. 5F




0.33%

FIG. 5G



19.60%

FIG. 5H




66.05%

9/17

FIG. 6A

Effect of Paclitaxel on Tu138 Cell Survival



10/17

FIG. 6B

Effect of Ceramide on Tu138 Cell Survival





FIG. 7

Time Kinetics of Combined Additions of Paclitaxel and Ceramide



12/17

FIG. 8
50% Isobologram Analysis of Paclitaxel and
Ceramide Exposed Tu138 cell survival





FIG. 9A


G₀-G₁: 59.1%

S: 33.5%

G₂-M: 7.4%

Control - No Additions (24 hours)

FIG. 9B


G₀-G₁: 56.7%

S: 26.8%

G₂-M: 16.5%

Ceramide 25 µg/ml (24 hours)

FIG. 9C


G₀-G₁: 9.5%

S: 28.7%

G₂-M: 61.8%

Paclitaxel 600 ng/ml (24 hours)


FIG. 9D

G₀-G₁: 17.2%

S: 37.2%

G₂-M: 45.6%Ceramide 25 µg/ml (24 hours)
+ Paclitaxel 600 ng/ml


FIG. 9E



G₀-G₁: 53.9%
S: 40.2%
G₂-M: 6.0%

Control - No additions (48 hours)


FIG. 9F



G₀-G₁: 54.9%
S: 39.6%
G₂-M: 5.5%

Ceramide 25 µg/ml (48 hours)


FIG. 9G



G₀-G₁: 16.7%
S: 25.2%
G₂-M: 58.2%

Paclitaxel 600 ng/ml (48 hours)

FIG. 9H



G₀-G₁: 71.6%
S: <1%
G₂-M: 28.4%

Ceramide 25 µg/ml (48 hours)
+ Paclitaxel 600 ng/ml

Time Kinetics Of The Induction Of Apoptosis By Paclitaxel And Ceramide Acting In Combination.


FIG. 10A

FIG. 10B


FIG. 10C

FIG. 10D


24 Hours Of Taxol And/Or Ceramide Exposure.




Control - no additions
Apoptosis: 8.7%



Ceramide (25 µg/ml)
Apoptosis: 9.7%



Paclitaxel (600 ng/ml)
Apoptosis: 18.35%



Ceramide 25 µg/ml
+ Paclitaxel 600 ng/ml
Apoptosis: 53.7%


FIG. 10E

FIG. 10F


FIG. 10G

FIG. 10H


48 Hours Of Taxol And/Or Ceramide Exposure.




Control - no additions
Apoptosis: 7.8%



Ceramide (25 µg/ml)
Apoptosis: 13.6%



Paclitaxel (600 ng/ml)
Apoptosis: 54.7%



Ceramide (25 µg/ml)
+ Paclitaxel 600 ng/ml
Apoptosis: 84.9%

FIG. 11 Growth of Human Squamous Carcinoma Cells in Nude Mice




FIG. 12 Excised Tumor Weights

